Literature DB >> 10619801

Risk of hospital admission for obstructive pulmonary disease in alpha(1)-antitrypsin heterozygotes of phenotype PiMZ.

N Seersholm1, J T Wilcke, A Kok-Jensen, A Dirksen.   

Abstract

Whether subjects heterozygous for alpha(1)-antitrypsin (alpha(1)-AT) deficiency are at risk for development of obstructive pulmonary disease (OPD) has been discussed for the past three decades. Both cohort and case-control studies have reached different conclusions, with the major problems being small sample sizes. A cohort of heterozygotes with the phenotype PiMZ was retrieved from the Danish Alpha(1)-Antitrypsin Deficiency Registry. Ten matched controls for each PiMZ subject were identified from the files of the Danish Central Population Registry. Cases and controls were subsequently linked to the files of the Danish Hospital Discharge Registry, and relative risk for OPD was calculated. In the cohort of 1,551 PiMZ subjects (11,678 person-years), we identified 47 subjects with a discharge diagnosis of OPD, as compared with 206 subjects with this diagnosis in the control group (109,748 person-years), yielding a relative risk (RR) of 2.2 (95% confidence interval [CI]: 1.5 to 3.0). This increased risk was present in both men and women and in all age groups; however, it was significant only in the age group from 40 to 79 yr. Of the 1,551 PiMZ subjects, 565 (36%) were first-degree relatives of PiZ index cases, and it appeared that only this group was at increased risk of hospital admission for OPD (RR: 3.4, 95% CI: 2.2 to 5.3). We conclude that alpha(1)-AT heterozygotes of phenotype PiMZ are at increased risk of hospital admission for OPD if they are first-degree relatives of PiZ index cases only, and that other, yet unknown genetic or environmental factors contribute to the development of lung disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10619801     DOI: 10.1164/ajrccm.161.1.9812131

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  16 in total

1.  Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline.

Authors:  Darcy D Marciniuk; P Hernandez; M Balter; J Bourbeau; K R Chapman; G T Ford; J L Lauzon; F Maltais; D E O'Donnell; D Goodridge; C Strange; A J Cave; K Curren; S Muthuri
Journal:  Can Respir J       Date:  2012 Mar-Apr       Impact factor: 2.409

2.  Polymorphisms in the HPC/ELAC-2 and alpha 1-antitrypsin genes that correlate with human diseases in a North Indian population.

Authors:  Ranbir C Sobti; Hitender Thakur; Lipsy Gupta; Ashok K Janmeja; Amlesh Seth; Sharwan K Singh
Journal:  Mol Biol Rep       Date:  2010-02-02       Impact factor: 2.316

3.  Alpha-1 Antitrypsin PiMZ Genotype Is Associated with Chronic Obstructive Pulmonary Disease in Two Racial Groups.

Authors:  Marilyn G Foreman; Carla Wilson; Dawn L DeMeo; Craig P Hersh; Terri H Beaty; Michael H Cho; John Ziniti; Douglas Curran-Everett; Gerard Criner; John E Hokanson; Mark Brantly; Farshid N Rouhani; Robert A Sandhaus; James D Crapo; Edwin K Silverman
Journal:  Ann Am Thorac Soc       Date:  2017-08

Review 4.  Pharmacogenetics of chronic obstructive pulmonary disease: challenges and opportunities.

Authors:  Craig P Hersh
Journal:  Pharmacogenomics       Date:  2010-02       Impact factor: 2.533

Review 5.  National Emphysema Treatment Trial state of the art: genetics of emphysema.

Authors:  Craig P Hersh; Dawn L DeMeo; Edwin K Silverman
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

Review 6.  Chronic obstructive pulmonary disease. 1: Susceptibility factors for COPD the genotype-environment interaction.

Authors:  A J Sandford; E K Silverman
Journal:  Thorax       Date:  2002-08       Impact factor: 9.139

Review 7.  Chronic obstructive pulmonary disease in alpha1-antitrypsin PI MZ heterozygotes: a meta-analysis.

Authors:  C P Hersh; M Dahl; N P Ly; C S Berkey; B G Nordestgaard; E K Silverman
Journal:  Thorax       Date:  2004-10       Impact factor: 9.139

8.  Clarification of the risk of chronic obstructive pulmonary disease in α1-antitrypsin deficiency PiMZ heterozygotes.

Authors:  Kevin Molloy; Craig P Hersh; Valerie B Morris; Tomás P Carroll; Catherine A O'Connor; Jessica A Lasky-Su; Catherine M Greene; Shane J O'Neill; Edwin K Silverman; Noel G McElvaney
Journal:  Am J Respir Crit Care Med       Date:  2014-02-15       Impact factor: 21.405

9.  Association between fibroblast growth factor 7 and the risk of chronic obstructive pulmonary disease.

Authors:  Si-cheng Xu; Jiang-ying Kuang; Jin Liu; Chun-lan Ma; Yu-lin Feng; Zhi-guang Su
Journal:  Acta Pharmacol Sin       Date:  2012-07-16       Impact factor: 6.150

10.  The Effects of Rare SERPINA1 Variants on Lung Function and Emphysema in SPIROMICS.

Authors:  Victor E Ortega; Xingnan Li; Wanda K O'Neal; Lela Lackey; Elizabeth Ampleford; Gregory A Hawkins; Philip J Grayeski; Alain Laederach; Igor Barjaktarevic; R Graham Barr; Christopher Cooper; David Couper; MeiLan K Han; Richard E Kanner; Eric C Kleerup; Fernando J Martinez; Robert Paine; Stephen P Peters; Cheryl Pirozzi; Stephen I Rennard; Prescott G Woodruff; Eric A Hoffman; Deborah A Meyers; Eugene R Bleecker
Journal:  Am J Respir Crit Care Med       Date:  2020-03-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.